JAK2 and acquired polycythemia vera: Activating mutations in the pseudo-kinase domain of JAK2, such as JAK2V617F, lead to ligand-independent phosphorylation of JAK2 and downstream activation of signalling pathways in patients with polycythemia vera (PV).